{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:54:49Z","timestamp":1782762889852,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R149-A10159-B120"],"award-info":[{"award-number":["R149-A10159-B120"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R90-A6143-14-S2"],"award-info":[{"award-number":["R90-A6143-14-S2"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00262-019-02473-y","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T13:02:52Z","timestamp":1578488572000},"page":"315-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3764-8578","authenticated-orcid":false,"given":"Morten Orebo","family":"Holmstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Cordua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibe","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Pallisgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ellervik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Carl","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads Hald","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"key":"2473_CR1","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1126\/science.183.4124.534","volume":"183","author":"O Stutman","year":"1974","unstructured":"Stutman O (1974) Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183:534\u2013536. https:\/\/doi.org\/10.1126\/science.183.4124.534","journal-title":"Science"},{"key":"2473_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrc797","volume":"2","author":"C Boshoff","year":"2002","unstructured":"Boshoff C, Weiss R (2002) Aids-related malignancies. Nat Rev Cancer 2:373\u2013382. https:\/\/doi.org\/10.1038\/nrc797","journal-title":"Nat Rev Cancer"},{"key":"2473_CR3","doi-asserted-by":"publisher","first-page":"a015677","DOI":"10.1101\/cshperspect.a015677","volume":"3","author":"JR Chapman","year":"2013","unstructured":"Chapman JR, Webster AC, Wong G (2013) Cancer in the transplant recipient. Cold Spring Harb Perspect Med 3:a015677. https:\/\/doi.org\/10.1101\/cshperspect.a015677","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2473_CR4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/CAD.0000000000000526","volume":"28","author":"M Cervinkova","year":"2017","unstructured":"Cervinkova M, Kucerova P, Cizkova J (2017) Spontaneous regression of malignant melanoma\u2014is it based on the interplay between host immune system and melanoma antigens? Anticancer Drugs 28:819\u2013830. https:\/\/doi.org\/10.1097\/CAD.0000000000000526","journal-title":"Anticancer Drugs"},{"key":"2473_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bjd.12111","volume":"168","author":"HE Teulings","year":"2013","unstructured":"Teulings HE, Overkamp M, Ceylan E et al (2013) Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. Br J Dermatol 168:162\u2013171. https:\/\/doi.org\/10.1111\/bjd.12111","journal-title":"Br J Dermatol"},{"key":"2473_CR6","first-page":"3863","volume":"93","author":"EF Posthuma","year":"1999","unstructured":"Posthuma EF, Falkenburg JH, Apperley JF et al (1999) HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood 93:3863\u20133865","journal-title":"Blood"},{"key":"2473_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0127637","volume":"10","author":"K Ku\u017eelov\u00e1","year":"2015","unstructured":"Ku\u017eelov\u00e1 K, Brodsk\u00e1 B, Fuchs O et al (2015) Altered HLA class I profile associated with type A\/D nucleophosmin mutation points to possible anti-nucleophosmin immune response in acute myeloid leukemia. PLoS ONE 10:1\u201312. https:\/\/doi.org\/10.1371\/journal.pone.0127637","journal-title":"PLoS ONE"},{"key":"2473_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000386035","volume":"13","author":"M Burnet","year":"1970","unstructured":"Burnet M (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13:1\u201327","journal-title":"Prog Exp Tumor Res"},{"key":"2473_CR9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD (2004) The three es of cancer immunoediting. Annu Rev Immunol 22:329\u2013360. https:\/\/doi.org\/10.1146\/annurev.immunol.22.012703.104803","journal-title":"Annu Rev Immunol"},{"key":"2473_CR10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting : from immuno- surveillance to tumor escape. Nat Immunol 3:991\u2013998. https:\/\/doi.org\/10.1038\/ni1102-991","journal-title":"Nat Immunol"},{"key":"2473_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrc3246","volume":"12","author":"T Blankenstein","year":"2012","unstructured":"Blankenstein T, Coulie PG, Gilboa E, Jaffee EM (2012) The determinants of tumour immunogenicity. Nat Rev Cancer 12:307\u2013313. https:\/\/doi.org\/10.1038\/nrc3246","journal-title":"Nat Rev Cancer"},{"key":"2473_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3670","volume":"14","author":"PG Coulie","year":"2014","unstructured":"Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14:135\u2013146. https:\/\/doi.org\/10.1038\/nrc3670","journal-title":"Nat Rev Cancer"},{"key":"2473_CR13","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior IA, Lewis PD, Mattos C (2012) A comprehensive survey of ras mutations in cancer. Cancer Res 72:2457\u20132467. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-2612","journal-title":"Cancer Res"},{"key":"2473_CR14","first-page":"2984","volume":"55","author":"H Qin","year":"1995","unstructured":"Qin H, Chen W, Takahasi M et al (1995) CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res 55:2984\u20132987","journal-title":"Cancer Res"},{"key":"2473_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1084\/jem.173.1.273","volume":"173","author":"S Jung","year":"1991","unstructured":"Jung S, Schluesener HJ (1991) Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 173:273\u2013276. https:\/\/doi.org\/10.1084\/jem.173.1.273","journal-title":"J Exp Med"},{"key":"2473_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/0198-8859(92)90334-J","volume":"33","author":"T Gedde-Dahl","year":"1992","unstructured":"Gedde-Dahl T, Eriksen JA, Thorsby E, Gaudernack G (1992) T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides. Hum Immunol 33:266\u2013274. https:\/\/doi.org\/10.1016\/0198-8859(92)90334-J","journal-title":"Hum Immunol"},{"key":"2473_CR17","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/ijc.25449","volume":"128","author":"S Wed\u00e9n","year":"2011","unstructured":"Wed\u00e9n S, Klemp M, Gladhaug IP et al (2011) Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 128:1120\u20131128. https:\/\/doi.org\/10.1002\/ijc.25449","journal-title":"Int J Cancer"},{"key":"2473_CR18","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/sj.bjc.6600697","volume":"88","author":"Y Shono","year":"2003","unstructured":"Shono Y, Tanimura H, Iwahashi M et al (2003) Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers. Br J Cancer 88:530\u2013536. https:\/\/doi.org\/10.1038\/sj.bjc.6600697","journal-title":"Br J Cancer"},{"key":"2473_CR19","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1158\/1078-0432.CCR-05-1672","volume":"12","author":"B Kubuschok","year":"2006","unstructured":"Kubuschok B, Neumann F, Breit R et al (2006) Naturally occurring T-cell response against mutated p21 Ras oncoprotein in pancreatic cancer. Clin Cancer Res 12:1365\u20131372. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1672","journal-title":"Clin Cancer Res"},{"key":"2473_CR20","first-page":"1071","volume":"1","author":"M Takahashi","year":"1995","unstructured":"Takahashi M, Chen W, Byrd DR et al (1995) Antibody to ras proteins in patients with colon cancer. Clin Cancer Res 1:1071\u20131077","journal-title":"Clin Cancer Res"},{"key":"2473_CR21","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1158\/0008-5472.CAN-05-1932","volume":"66","author":"R Somasundaram","year":"2006","unstructured":"Somasundaram R, Swoboda R, Caputo L et al (2006) Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res 66:3287\u20133293. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1932","journal-title":"Cancer Res"},{"key":"2473_CR22","first-page":"1315","volume":"90","author":"NM Butt","year":"2005","unstructured":"Butt NM, Rojas JM, Wang L et al (2005) Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. Haematologica 90:1315\u20131323","journal-title":"Haematologica"},{"key":"2473_CR23","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00262-009-0703-x","volume":"58","author":"S Rusakiewicz","year":"2009","unstructured":"Rusakiewicz S, Madrigal A, Travers P, Dodi AI (2009) BCR\/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors. Cancer Immunol Immunother 58:1449\u20131457. https:\/\/doi.org\/10.1007\/s00262-009-0703-x","journal-title":"Cancer Immunol Immunother"},{"key":"2473_CR24","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon SP, Xu L, Yang G et al (2012) MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med 367:826\u2013833. https:\/\/doi.org\/10.1056\/NEJMoa1200710","journal-title":"N Engl J Med"},{"key":"2473_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2016.1219825","volume":"6","author":"A Nelde","year":"2017","unstructured":"Nelde A, Walz JS, Kowalewski DJ et al (2017) HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. Oncoimmunology 6:1\u201311. https:\/\/doi.org\/10.1080\/2162402X.2016.1219825","journal-title":"Oncoimmunology"},{"key":"2473_CR26","doi-asserted-by":"publisher","first-page":"e1321184","DOI":"10.1080\/2162402X.2017.1321184","volume":"6","author":"JS Nielsen","year":"2017","unstructured":"Nielsen JS, Chang AR, Wick DA et al (2017) Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncoimmunology 6:e1321184. https:\/\/doi.org\/10.1080\/2162402X.2017.1321184","journal-title":"Oncoimmunology"},{"key":"2473_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMoa041974","volume":"352","author":"B Falini","year":"2005","unstructured":"Falini B, Mecucci C, Tiacci E et al (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254\u2013266. https:\/\/doi.org\/10.1056\/NEJMoa041974","journal-title":"N Engl J Med"},{"key":"2473_CR28","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1182\/blood-2013-04-496844","volume":"122","author":"J Greiner","year":"2013","unstructured":"Greiner J, Schneider V, Schmitt M et al (2013) Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). Blood 122:1087\u20131088","journal-title":"Blood"},{"key":"2473_CR29","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1084\/jem.190.5.705","volume":"190","author":"MJ Pittet","year":"1999","unstructured":"Pittet MJ, Valmori D, Dunbar PR et al (1999) High frequencies of naive Melan-A\/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190:705\u2013715. https:\/\/doi.org\/10.1084\/jem.190.5.705","journal-title":"J Exp Med"},{"key":"2473_CR30","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1056\/NEJMra1406186","volume":"376","author":"JL Spivak","year":"2017","unstructured":"Spivak JL (2017) Myeloproliferative neoplasms. N Engl J Med 376:2168\u20132181. https:\/\/doi.org\/10.1056\/NEJMra1406186","journal-title":"N Engl J Med"},{"key":"2473_CR31","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1182\/blood-2008-03-077966","volume":"112","author":"RL Levine","year":"2008","unstructured":"Levine RL, Gilliland DG (2008) Myeloproliferative disorders. Blood 112:2190\u20132198. https:\/\/doi.org\/10.1182\/blood-2008-03-077966","journal-title":"Blood"},{"key":"2473_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387\u2013397. https:\/\/doi.org\/10.1016\/j.ccr.2005.03.023","journal-title":"Cancer Cell"},{"key":"2473_CR33","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AAS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779\u20131790. https:\/\/doi.org\/10.1056\/NEJMoa051113","journal-title":"N Engl J Med"},{"key":"2473_CR34","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391\u20132405. https:\/\/doi.org\/10.1056\/NEJMoa1312542","journal-title":"N Engl J Med"},{"key":"2473_CR35","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379\u20132390. https:\/\/doi.org\/10.1056\/NEJMoa1311347","journal-title":"N Engl J Med"},{"key":"2473_CR36","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/leu.2016.233","volume":"30","author":"MO Holmstr\u00f6m","year":"2016","unstructured":"Holmstr\u00f6m MO, Riley CH, Svane IM et al (2016) The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms. Leukemia 30:2413\u20132416. https:\/\/doi.org\/10.1038\/leu.2016.233","journal-title":"Leukemia"},{"key":"2473_CR37","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/leu.2017.214","volume":"32","author":"MO Holmstr\u00f6m","year":"2018","unstructured":"Holmstr\u00f6m MO, Martinenaite E, Ahmad SM et al (2018) The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia 32:429\u2013437. https:\/\/doi.org\/10.1038\/leu.2017.214","journal-title":"Leukemia"},{"key":"2473_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41408-018-0166-4","volume":"9","author":"MO Holmstr\u00f6m","year":"2019","unstructured":"Holmstr\u00f6m MO, Ahmad SM, Klausen U et al (2019) High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals. Blood Cancer J 9:8. https:\/\/doi.org\/10.1038\/s41408-018-0166-4","journal-title":"Blood Cancer J"},{"key":"2473_CR39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.leukres.2019.02.010","volume":"79","author":"JC Wang","year":"2019","unstructured":"Wang JC, Chen C, Kundra A et al (2019) Programmed cell death receptor (PD-1) ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms. Leuk Res 79:52\u201359. https:\/\/doi.org\/10.1016\/j.leukres.2019.02.010","journal-title":"Leuk Res"},{"key":"2473_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00002371-200203000-00001","volume":"25","author":"U Keilholz","year":"2002","unstructured":"Keilholz U, Weber J, Finke JH et al (2002) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97\u2013138","journal-title":"J Immunother"},{"key":"2473_CR41","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1182\/blood.2019001113","volume":"134","author":"S Cordua","year":"2019","unstructured":"Cordua S, Kjaer L, Skov V et al (2019) Prevalence and phenotypes of JAK2 V617F and Calreticulin mutations in a Danish general population. Blood 134:469\u2013479. https:\/\/doi.org\/10.1182\/blood.2019001113","journal-title":"Blood"},{"key":"2473_CR42","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1089\/10430340050015581","volume":"11","author":"C-L Hsieh","year":"2002","unstructured":"Hsieh C-L, Chen D-S, Hwang L-H (2002) Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum Gene Ther 11:681\u2013692. https:\/\/doi.org\/10.1089\/10430340050015581","journal-title":"Hum Gene Ther"},{"key":"2473_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2019.1633634","volume":"1","author":"MO Holmstr\u00f6m","year":"2019","unstructured":"Holmstr\u00f6m MO, Novotny GW, Petersen J et al (2019) Progression of JAK2- mutant polycythemia vera to CALR -mutant myelofibrosis severely impacts on disease phenotype and response to therapy. Leuk Lymphoma 1:1\u20134. https:\/\/doi.org\/10.1080\/10428194.2019.1633634","journal-title":"Leuk Lymphoma"},{"key":"2473_CR44","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/J.CTRV.2014.12.013","volume":"41","author":"F Massari","year":"2015","unstructured":"Massari F, Santoni M, Ciccarese C et al (2015) PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev 41:114\u2013121. https:\/\/doi.org\/10.1016\/J.CTRV.2014.12.013","journal-title":"Cancer Treat Rev"},{"key":"2473_CR45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00281-018-0693-x","volume":"41","author":"MO Holmstr\u00f6m","year":"2019","unstructured":"Holmstr\u00f6m MO, Hasselbalch HC (2019) Cancer immune therapy for myeloid malignancies: present and future. Semin Immunopathol 41:97\u2013109. https:\/\/doi.org\/10.1007\/s00281-018-0693-x","journal-title":"Semin Immunopathol"},{"key":"2473_CR46","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00262-010-0875-4","volume":"59","author":"Z Moodie","year":"2010","unstructured":"Moodie Z, Price L, Gouttefangeas C et al (2010) Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 59:1489\u20131501. https:\/\/doi.org\/10.1007\/s00262-010-0875-4","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02473-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02473-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02473-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:20:32Z","timestamp":1609978832000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02473-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["2473"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02473-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]},"assertion":[{"value":"26 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Morten Orebo Holmstr\u00f6m, Mads Hald Andersen, and Hans Carl Hasselbalch have filed a patent regarding <i>CALR<\/i> exon 9 mutations as targets for cancer immune therapy. The patent has been transferred to Zealand University Hospital, Zealand Region and to Herlev Hospital, Capital Region, Denmark, according to Danish Law concerning inventions created at public research institutions. The authors declare that there are no other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All projects described herein were approved by the local Ethics Committee in Zealand Region, Denmark, with the approval numbers: SJ-456, SJ-585, SJ-114, SJ-113, and SJ-452.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"All patients and healthy donors provided both written and oral informed consent on the use of their biological material for research and for publication. The consent was received before the sampling of biological material from the individual.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}